Orchid Pharma Limited has released its investor presentation covering the quarter ended December 31, 2025 (Q3 FY26). Total Sales for the quarter stood at ₹207 Cr, a 5% decline year-over-year. While EBITDA saw a significant 65% drop to ₹13 Cr, the company managed to post a consolidated Profit Before Tax (PBT) of -₹6 Cr, compared to a profit of ₹24 Cr in Q3-25. Gross Margins compressed sharply to 31% for the quarter.
Orchid Pharma Q3 FY26 Financial Highlights
Orchid Pharma Limited disclosed its financial results for the third quarter of the fiscal year 2026 (ending December 31, 2025), alongside performance figures for the nine months ending the same date. The presentation highlights key movements in revenue, profitability, and margins compared to the previous corresponding periods.
Key Performance Indicators (Q3 Comparison)
The top-line performance showed a slight contraction:
- Sales: Declined by 5% to ₹207 Cr in Q3-26 from ₹217 Cr in Q3-25.
- Other Income: Increased by 10% to ₹11 Cr.
- EBITDA*: Experienced a substantial decrease of 65%, falling to ₹13 Cr (from ₹37 Cr in Q3-25).
- PBT & PAT: The company reported a loss of -₹6 Cr, contrasting with a profit of ₹24 Cr in the year-ago quarter.
Nine-Month (9M) Performance Summary
Over the first nine months of FY26, the overall trend reflected challenges:
- Total Sales were ₹574 Cr, down 16% from ₹684 Cr in 9M-25.
- EBITDA for the nine months stood at ₹58 Cr, representing a 50% reduction compared to 9M-25’s ₹115 Cr.
- Profit Before Tax (PBT) for 9M-26 was ₹15 Cr, significantly lower than ₹78 Cr recorded in 9M-25.
Analysis of Margins and Expenses (Q3)
Expense management and gross profitability were key areas of change:
Gross Margin Analysis
The Gross Margin as a percentage of Sales deteriorated significantly in Q3-26, reaching 31%. This compares unfavorably to the previous periods, notably dropping from 43% in Q3-25 and a high of 45% in Q3-24. This indicates increased pressure on the cost of goods sold relative to revenue.
Operating Expenses as % to Sales
Employee benefits (Emp Benefit) expenses saw a minor increase to 11% of sales in Q3-26 (up from 10% in Q3-25). Other Expenses decreased to 18% of sales (down from 20% in Q3-25), contributing to a slightly improved overall expense ratio relative to sales compared to some prior periods.
Profitability Margins
The trend in profitability ratios shows a sharp downturn for Q3-26:
- EBITDA margin fell to 6% (from 17% in Q3-25).
- PBT margin dropped into negative territory at -3% (from 11% in Q3-25).
Company Communication
The management confirmed that this investor presentation was provided in relation to the Earnings Call scheduled for February 12, 2026. All figures presented are based on a standalone basis, and shareholders are advised to refer to the detailed financials for exact numbers.
Source: BSE
